Published in JACC: Clinical Electrophysiology 📄 First dedicated trial of SBRT for refractory VT in Chagas cardiomyopathy — significant reduction in arrhythmia burden, safely delivered. Part of my PhD thesis at FMUSP.
https://t.co/BkqrB6L4cz
#RadOnc#SBRT#STAR#Arrhythmia
The #PROTEUS trial contributes important knowledge to the evolving evidence on high-risk #prostatecancer treatment options. ASTRO’s new summary document from @NehaVapiwala and @AmarUKishan is a member resource for discussions with your #multidisciplinary colleagues and patients.
https://t.co/HywTq0w7oa
In summary, the role of RP in the setting of oligometastatic or low-burden mHSPC remains to be proven.
IMHO, the authors' conclusion in the RAMPP paper is a bit overreaching, and I don't think the results robustly support the addition of RP in this setting.
I'm eager to know what others think about these results
END
9/9
I am really excited with this… our first patient with Chagas Disease that underwent SBRT in July/21 now had a better LVEF than before (and also no recurrence)! Any thoughts?@DoctorPhillEP @crpisani@Scanav1Mauricio@besalva@EPeeps_Bot@SobracO
@besalva comenta o Fase 3 NRG Oncology/RTOG 1112, apresentado no #ASTRO22, que demonstrou que adicionar SBRT à sorafenibe em pts com CA fígado avançado confere benefício de SG e retarda a progressão da doença sem comprometer a QV - https://t.co/WvdVubwE6f @ASTRO_org#ONCONEWS
@besalva, médico especialista em radioterapia do @Icesp_ e do HCorOnco comenta o fase III NRG Oncology GU003 apresentado no #ASTRO21, que avaliou a radioterapia hipofracionada no tto de pts com CA próstata pós-prostatectomia vs a RT convencional - https://t.co/1wlyVS2isV